A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold, potentially eliminating ...

The FDA expanded the approval of mirikizumab (Omvoh) to include treatment of adults with moderately to severely active ...

Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with chronic idiopathic constipation, regardless of age, BMI or renal function ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in inflammatory bowel disease (IBD), Mount Sinai researchers have shown in a ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Wearable devices can identify, differentiate, and predict flare-ups, or the worsening of symptoms and inflammation, in ...

Tulisokibart, a TNF–like cytokine 1A monoclonal antibody, has demonstrated significant potential in inducing clinical ...

Kochhar et al, Comparative Effectiveness of Upadacitinib and Tofacitinib in Ulcerative Colitis: A US Propensity-Matched Cohort Study, American Journal of Gastroenterology (2024). DOI: 10.14309/ajg.

Crohn’s disease and ulcerative colitis (UC) are both types of inflammatory bowel disease (IBD) that share similar symptoms but differ in their affected areas, disease progression, and treatment ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes compared with tofacitinib.